Connect with us

Health

Study Suggests Weight-Loss and Diabetes Drugs May Reduce Overdose and Alcohol Intoxication Rates

Published

on

A new study has found that popular weight-loss and diabetes drugs, such as Ozempic (semaglutide) and Saxenda (liraglutide), may help reduce the rates of opioid overdoses and alcohol intoxication among individuals with substance use disorders. Published in the scientific journal Addiction, the research suggests that these drugs, which are part of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist class, could play a role in addressing substance abuse.

The study analyzed electronic health records from a U.S. database that spanned more than 136 health systems, including data from over 500,000 individuals with opioid use disorder and 800,000 with alcohol use disorder. Among these, approximately 8,100 people with opioid use disorder and 5,600 with alcohol use disorder had prescriptions for GIP/GLP-1 receptor agonists, such as Ozempic, Victoza, and Trulicity.

Findings showed that individuals using these drugs had a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication. Researchers believe this class of drugs, which mimics hormones in the intestine to trigger insulin production and promote a sense of fullness after eating, may also affect neural pathways related to reward, motivation, and addiction.

“The advantage of this study is the large dataset, which goes back to 2014,” said Alexandra DiFeliceantonio, associate director of Virginia Tech’s Center for Health Behaviors Research. However, she noted that the study is not a controlled trial, meaning other factors could have influenced the results. Despite this, DiFeliceantonio emphasized the importance of such research, adding, “There’s a lot more work to be done and medications to test in this area.”

While animal studies have shown similar results, experts say that more randomized, controlled trials are needed to confirm these findings. Dr. Lorenzo Leggio, a physician-scientist at the U.S. National Institutes of Health, highlighted the need for further research. “We’re missing the double-blind, placebo-controlled randomized clinical trials,” he said.

Researchers believe these findings are crucial, as opioid overdoses and alcohol intoxication remain significant public health concerns. In the U.S., over 100,000 drug overdoses were reported in 2022 and 2023, a far higher rate than in Europe. Alcohol use is also a widespread issue, particularly in the European Union, which the World Health Organization has called the “heaviest-drinking area globally.”

Experts like Dr. Fares Qeadan, the study’s lead author, suggest that GIP and GLP-1 receptor agonists could offer new, less stigmatized treatment options for substance use disorders. “With further validation, these medications might broaden the toolkit for managing opioid and alcohol use disorders, helping more people avoid relapse, overdose, and severe health consequences,” Qeadan said.

As evidence grows, future research will focus on understanding how these drugs impact addiction-related behaviors, as well as exploring their long-term effectiveness in diverse populations.

Health

Study Links Hormonal IUDs to Slightly Increased Breast Cancer Risk in Young Women

Published

on

By

Copenhagen, Denmark — A recent study from the Danish Cancer Institute has found that hormone-releasing intrauterine devices (IUDs) may be associated with a slightly higher risk of breast cancer among young women. The large-scale study, published in the Journal of the American Medical Association (JAMA), has prompted health professionals to reconsider the risks and benefits of hormonal contraceptives.

The research examined health outcomes for around 79,000 women, aged 15 to 49, who used hormonal IUDs, such as the Mirena coil, compared to a similar group of women who did not use any form of hormonal birth control. The women were monitored over an average of 6.8 years. While the overall risk of developing breast cancer remained low, the study found that hormonal IUD users faced a slightly higher risk—about 14 additional cases of breast cancer per 10,000 women.

Hormonal IUDs, which release a progesterone-like hormone to prevent pregnancy, are commonly used across Europe, with about 8.1% of reproductive-age women relying on this form of contraception. Unlike copper IUDs, which do not involve hormones, devices like the Mirena coil work by slowly releasing hormones directly into the uterus. Many medical professionals had previously believed this localized hormone release posed a lower risk of breast cancer compared to oral contraceptive pills, which expose the body to higher levels of hormones.

However, the new findings challenge this assumption. “The results of this study are highly unexpected,” said Dr. Channa Jayasena, a reproductive endocrinologist at Imperial College London, who was not involved in the research.

The study has limitations, as it did not account for lifestyle factors like smoking, alcohol consumption, and obesity, all of which are known breast cancer risk factors. These unmeasured variables could influence the study’s results, but the data has nonetheless raised concerns.

Doctors and researchers are now advising that healthcare providers include potential breast cancer risks when discussing hormonal IUDs with patients. “My advice for women is that breast cancer risk caused by [IUDs] is not established but warrants a closer look,” Jayasena added.

This is not the first study to suggest a link between hormonal contraceptives and breast cancer. Last year, researchers at the University of Oxford found that progestogen-only contraceptives, regardless of their form, were associated with a slight increase in breast cancer risk. Experts suggest that the increased risk from IUDs may be similar to that posed by oral contraceptives.

Despite the findings, there remains broad medical consensus that the benefits of hormonal contraception outweigh the risks. Dr. Mangesh Thorat, a breast cancer surgeon and researcher at Queen Mary University of London, noted that certain types of IUDs have been shown to reduce the risks of cervical, endometrial, and ovarian cancers.

Thorat also highlighted that contraceptive risks change with age, suggesting that women nearing 40 should consider non-hormonal alternatives in consultation with their healthcare providers.

Continue Reading

Health

Ukraine’s Healthcare Reforms Align with EU Standards Amid Ongoing War, Says WHO Official

Published

on

By

Kyiv, Ukraine – Ukraine’s healthcare system, under immense strain from the ongoing war with Russia, is simultaneously undergoing critical reforms aimed at aligning with European Union (EU) standards. According to a senior official from the World Health Organization (WHO), these efforts are positioning Ukraine to meet key EU regulations, even as the country grapples with daily attacks on its health facilities.

Jarno Habicht, head of the WHO office in Ukraine, highlighted the country’s dual challenge of addressing immediate healthcare needs while preparing for future EU membership talks. “Ukraine is responding every day,” Habicht said in an interview with Euronews. “Ambulances are supporting civilians, but there is also the challenge of rebuilding destroyed infrastructure.”

Since Russia’s full-scale invasion, attacks on healthcare facilities have increased sharply, with nearly daily incidents reported since December 2023. Despite these challenges, Ukraine is continuing to push forward with health sector reforms initiated before the conflict. Habicht noted that these reforms are critical as Ukraine harmonizes its public health legislative framework with EU standards, a key step in the country’s eventual accession process.

Aligning Healthcare with EU Regulations

While healthcare policy largely remains under the control of individual EU member states, certain areas—such as cross-border patient movement—require greater alignment. Habicht emphasized the importance of harmonizing regulations to ensure consistency in healthcare for Ukrainians, both within the country and in neighboring EU states where many have sought care due to the war.

Several national health frameworks will need to be adjusted to EU law, including regulations on water quality, cosmetics, chemicals, and rules governing tobacco and alcohol. One critical area of focus is the pharmaceutical sector. Ukraine, once home to one of the largest drug manufacturing industries in Central and Eastern Europe, has seen a significant portion of its industry devastated by the conflict. Harmonizing drug manufacturing standards, regulatory practices, and marketing authorizations with EU guidelines will be essential as the country rebuilds.

In July 2022, Kyiv adopted a new law regulating pharmaceutical products, which aims to prepare the sector for alignment with EU standards. This, according to Habicht, is a key step in Ukraine’s path to EU membership. “Ukraine’s reform efforts and the required harmonization with EU legislation basically go in the same direction,” he said.

Health System Under Siege

Since the war began, the WHO has recorded 1,940 attacks on healthcare facilities in Ukraine, the highest number in any humanitarian crisis to date. In addition to direct strikes on hospitals and clinics, critical infrastructure such as energy systems has been severely impacted. Russia’s large-scale attacks on Ukraine’s power grid have left millions without reliable access to electricity, heating, and water—further complicating the delivery of essential healthcare services.

Habicht warned that as winter approaches, the situation could worsen. “The latest estimate shows the average Ukrainian household is without electricity for six hours a day,” he said. This lack of power is not only affecting healthcare facilities but also schools, businesses, and homes across 20 of Ukraine’s 24 regions.

The war has also exacerbated poverty, with the national poverty rate rising from 7% to 25%. Many Ukrainians are now struggling to afford basic necessities, including medicine. Humanitarian organizations, supported by the WHO, are working to provide free medicines to approximately 12% of unemployed individuals in frontline areas.

Despite the dire circumstances, Ukraine continues its efforts to reform and rebuild, with its sights set on future integration with the EU.

Continue Reading

Health

European Nations and Non-Profits Pledge $700 Million to WHO for Global Health Initiatives

Published

on

By

Berlin, Germany – A coalition of European countries and non-profit organizations has committed $700 million (€627.4 million) to the World Health Organization (WHO) to support its efforts in tackling global health challenges. The announcement was made at the World Health Summit in Berlin, as the WHO pushes for more financial flexibility in how it allocates its resources.

This new funding, combined with an earlier pledge of $300 million (€268.9 million) from the European Union and the African Union, brings the total contribution to $1 billion (€896.3 million). The funds will be used by the WHO to combat preventable diseases and target 40 million preventable deaths over the next four years.

Germany emerged as the largest contributor, pledging nearly $400 million (€358.5 million), including $262.6 million (€234.8 million) in new money. Other European countries, including Norway, Luxembourg, Denmark, and Ireland, also made significant contributions. These funds are seen as crucial in providing the WHO with the financial stability it needs to respond to global health crises and long-term health challenges.

WHO’s Push for Flexible Funding

Historically, the WHO’s funding has come from a mix of member state contributions and voluntary donations from governments and non-profits. Much of this money is earmarked for specific health programs, limiting the organization’s ability to allocate resources as needed. This has made it difficult for the WHO to retain staff, plan long-term initiatives, or pivot quickly in the face of emergencies like the COVID-19 pandemic.

To address these challenges, countries agreed in 2022 to increase their membership dues to cover 50% of the WHO’s core budget by 2030, up from just 13% in 2022. This move aims to ensure the organization has a more predictable and flexible financial foundation.

At the summit, German Chancellor Olaf Scholz emphasized the importance of this shift. “The WHO’s work benefits us all. What it needs for this work is sustainable financing that gives it the certainty to plan ahead and the flexibility to react,” he said.

European Support for Global Health

European Commission President Ursula von der Leyen described the WHO as the world’s “collective first line of defence against health crises and inequalities.” She highlighted the EU’s €250 million investment announced earlier this year to address global health issues, including mpox, cholera, and the Marburg virus. Additionally, von der Leyen committed over €75 million to support the WHO’s mRNA technology hub in South Africa, which aims to boost vaccine production in low- and middle-income countries.

Non-Profits and Pharmaceutical Companies Join the Effort

Several global health non-profits, including Wellcome, Resolve to Save Lives, and the World Diabetes Foundation, pledged more than $130 million (€116.5 million) to support the WHO. Pharmaceutical companies Sanofi, Boehringer Ingelheim, and Novo Nordisk also committed to backing the organization’s efforts.

WHO Director-General Dr. Tedros Adhanom Ghebreyesus expressed gratitude for the contributions but acknowledged the challenging financial environment. “We know that we are making this ask at a time of competing priorities and limited resources,” he said, adding, “every contribution counts.”

The WHO is expected to seek further commitments during the upcoming G20 summit in Brazil, as it continues to bolster its financial capacity to address global health threats.

Continue Reading

Trending